(2023)
Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203).
BIOMEDICINE & PHARMACOTHERAPY.
167,
(2023)
Establishment of an LC-MS/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES.
1229,
(2023)
Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography-Tandem Mass Spectrometry Analysis in Rats.
SEPARATIONS.
10,
5
(2023)
Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES.
123688,
1
(2023)
Development of an LC–MS/MS Assay and Toxicokinetic Characterization of Hexamethylenetetramine in Rats.
TOXICS.
11,
41
(2023)
Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis.
JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY.
14,
19
(2023)
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.
67,
1
(2022)
Toxicokinetics, Percutaneous Absorption and Tissue Distribution of Benzophenone-3, an UV Filtering Agent, in Rats.
TOXICS.
10,
11
(2022)
Combined phototherapy with metabolic reprogramming-targeted albumin nanoparticles for treating breast cancer.
BIOMATERIALS SCIENCE.
10,
24
(2022)
Dynamic drug release state and PEG length in PEGylated liposomal formulations define the distribution and pharmacological performance of drug.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY.
76,
(2022)
Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand, Lu-177-DOTA-PSMA-GUL, in rats by using LC-MS/MS.
SCIENTIFIC REPORTS.
12,
1
(2022)
Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study.
PHARMACEUTICS.
14,
6
(2022)
Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis.
MOLECULES.
27,
6
(2022)
Comparison of the exposure assessment of di(2-ethylhexyl) phthalate between the PBPK model-based reverse dosimetry and scenario-based analysis: A Korean general population study.
CHEMOSPHERE.
294,
(2022)
Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
JOURNAL OF CONTROLLED RELEASE.
343,
(2022)
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.
66,
1
(2021)
Pharmacokinetics of panduratin a following oral administration of a Boesenbergia pandurata extract to rats.
JOURNAL OF FOOD AND DRUG ANALYSIS.
29,
4
(2021)
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
CLINICAL PHARMACOLOGY & THERAPEUTICS.
109,
4
(2021)
Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity.
ADVANCED THERAPEUTICS.
4,
2
(2021)
Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.
ANTICANCER RESEARCH.
41,
2
Publications
(2020)
약학용어집.
신일서적(주).
Co-author
(2019)
약제학 리뷰 (수정 2판).
도서출판 신일북스.
Co-author
(2019)
생물약제학과 약동학 (수정2판).
도서출판 신일북스.
Co-author
Patent/Intellectual Property
GASTRORETENTIVE DRUG DELIVERY DEVICE HAVING EXPANDABLE STRUCTURE AND MANUFACTURING METHOD THEREFOR.
17030064.
20220728.
UNITED STATES
방출 속도 조절 경구용 약물 전달 장치 및 방출 속도 조절 경구용 약물 전달 장치의 제조 방법.
10-2020-0046821.
20220725.
KOREA, REPUBLIC OF
확장형 구조를 갖는 위체류 약물전달장치 및 이의 제조 방법.
10-2020-0058895.
20220620.
KOREA, REPUBLIC OF
확장형 구조를 갖는 위체류 약물전달장치 및 이의 제조 방법.
10-2020-0058892.
20211223.
KOREA, REPUBLIC OF
위체류 제어 방출형 제제.
10-2018-0037362.
20200513.
KOREA, REPUBLIC OF
Conference Paper
(2023)
Development of 3D-printed expanding gastroretentive drug delivery system by applying the design of experiment approach.
2023 International Conference of the Korean Society of Pharmaceutical Sciences and Technology.
KOREA, REPUBLIC OF
(2023)
Nonlinear pharmacokinetics of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide in rats.
2023 International Conference of the Korean Society of Pharmaceutical Sciences and Technology.
KOREA, REPUBLIC OF
(2023)
Pharmacokinetics of the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Semaglutide in Rats.
2023 PharmSci 360.
UNITED STATES
(2023)
Extended In Vitro-In Vivo Correlation (IVIVC) Model to Predict the Pharmacokinetics of Ticagrelor Sustained-Release Formulations.
2023 PharmSci 360.
UNITED STATES
(2023)
Pharmacokinetics and Interspecies Scaling of Semaglutide, a GLP-1 Receptor Agonist.
2023 PharmSci 360.
UNITED STATES
(2023)
Development of Oral Bi-layer Tablet of Ruxolitinib.
2023 PharmSci 360.
UNITED STATES
(2023)
Development of a Novel Repeat-action Oral Drug Delivery System for Naproxen and Esomeprazole.
2023 PharmSci 360.
UNITED STATES
(2023)
Prediction of in vivo pharmacokinetics for ticagrelor sustained-release formulations via extended IVIVC model.
CRS 2023 Annual Meeting & Exposition.
UNITED STATES
(2023)
Application of extended IVIVC model to develop sustained-release injections for semaglutide, a GLP-1 receptor agonist.
2023 대한약학회 춘계 국제학술대회.
KOREA, REPUBLIC OF
(2023)
Novel pulsatile release drug delivery systems of naproxen and esomeprazole: in vitro and in vivo evaluations.
2023 대한약학회 춘계 국제학술대회.
KOREA, REPUBLIC OF
(2022)
Evaluation of regional brain distribution of semaglutide, a GLP-1 analog, in rats by LC-MS/MS.
2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.
KOREA, REPUBLIC OF
(2022)
Development of an LC-MS/MS method for the determination of liraglutide, a GLP-1 receptor agonist, to characterize the pharmacokinetics and brain distribution in rats.
2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.
KOREA, REPUBLIC OF
(2022)
Development of oral sustained-release tablet of ruxolitinib.
2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.
KOREA, REPUBLIC OF
(2022)
In vitro Release and in vivo PK Profiles of Fulvestrant Sustained Release Formulations with Improved Solubility.
2022 International Coference of the Korean Society of Pharmaceutical Sciences ans Technology.
KOREA, REPUBLIC OF
(2022)
Brain Distribution of the Therapeutic Peptide Liraglutide by a Novel Liquid Chromatography-Tandem Mass Spectrometry.
2022 Fall International Convention of The Pharmaceutical Society of Korea.
KOREA, REPUBLIC OF
(2022)
Establishment of In Vitro-In Vivo Correlation (IVIVC) for Aceclofenac with the Active Metabolite Diclofenac.
2022 PharmSci 360 (AAPS).
UNITED STATES
(2022)
Novel LC-MS/MS analyses for Glucagon-Like Peptide-1 (GLP-1) Analogs, Liraglutide, Lixisenatide, and Semaglutide, and Pharmacokinetic Evaluation in Rats.
2022 PharmSci 360 (AAPS).
UNITED STATES
(2022)
Pharmacokinetics and Brain Distribution of the Therapeutic Peptide Semaglutide by a Novel Liquid Chromatography-Tandem Mass Spectrometry.
2022 PharmSci 360 (AAPS).
UNITED STATES
(2021)
Establishment of an IVIVC model for the development of sustained-release formulations: the aceclofenac case study.
2021 Fall International Convention of The Pharmaceutical Society of Korea.
KOREA, REPUBLIC OF
(2021)
Novel model-based approach for the development of sustained-release injections for liraglutide by applying extended DoE-IVIVC model.
2021 Fall International Convention of The Pharmaceutical Society of Korea.
KOREA, REPUBLIC OF
